Screener
Acadia Pharmaceuticals ACAD Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
FAQ
- What is Acadia Pharmaceuticals's total equity?
- Acadia Pharmaceuticals (ACAD) reported total equity of $1.31B in Q2 2026.
- How has Acadia Pharmaceuticals's total equity changed year-over-year?
- Acadia Pharmaceuticals's total equity increased by 58.9% year-over-year, from $822.38M to $1.31B.
- What is the long-term trend for Acadia Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Acadia Pharmaceuticals's total equity has grown at a 14.4% compound annual growth rate (CAGR), from $627.01M to $1.23B.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.
Ask your AI about Acadia Pharmaceuticals's total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude